INfluenza-Associated central nervous system dysfunction in taiwanese children clinical characteristics and outcomes with and without administration of oseltamivir

Pediatric Infectious Disease Journal

Volumn 28, Issue 7, 2009, Pages 647-648

  Huang, Yhu Chering ^a,b   Li, Wen Chen ^a,b   Tsao, Kuo Chien ^b,c   Huang, Chung Guei ^b,c   Chiu, Cheng Hsun ^a,b   Lin, Tzou Yien ^a,b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Central nervous system; Delirium; Encephalitis; Encephalopathy; Influenza

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR;

ADOLESCENT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; FEMALE; HUMAN; INFANT; INFLUENZA; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; TAIWAN; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; TAIWAN; TREATMENT OUTCOME;

EID: 70350031312     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181986bf9     Document Type: Review

References (12)

1. Lin CH, Huang YC, Chiu CH, et al. Neurologic manifestations in children with influenza B virus infection. Pediatr Infect Dis J. 2006;25:1081-1083.
2. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. J Pediatr. 2007;150:306-310. (Pubitemid 46328959)
3. Togashi T, Matsuzono Y, Narita M, et al. Influenza-associated acute encephalopathy in Japanese children in 1994-2002. Virus Res. 2004;103: 75-78. (Pubitemid 38649063)
4. Huang YC, Lin TY, Wu SL, et al. Influenza A-associated central nervous system dysfunction in children presenting as transient visual hallucination. Pediatr Infect Dis J. 2003;22:366-368.
5. Nicholson KG, Aoki FY, Osterhaus AD, et al; Neuraminidase Inhibitor Flu Treatment Investigator Group. Efficacy and safety of oseltamivir in treat-ment ofacute influenza: a randomized controlled trial. Lancet. 2000;355: 1845-1850. (Pubitemid 30311875)
6. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133. (Pubitemid 32151932)
7. Dutkowski R, Thakrar B, Froehlich E, et al. Safety and pharmacology of oseltamivir in clinical use. Drug Safe. 2003;26:787-801. (Pubitemid 37056109)
8. Goshima N, Nakano T, Nagao M, et al. A clinical study of abnormal behaviors in patients with influenza. Infect Immu Child. 2006;18:371-376.
9. Okumura A, Kubota T, Kato T, et al. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J. 2006;25:572. (Pubitemid 43863379)
10. Toovey S, Rayner CR, Prinssen E, et al. Post-marketing safety assessment ofneuropsychiatric adverse event risk in patients with influenza treated with oseltamivir. In: Program and Abstracts of the International Symposium on Respiratory Viral Infections; February 28-March 2, 2008; Singapore. Abstract X.
11. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med Gen Med. 2007;9:23.
12. Wilcox M, Zhu S. Oseltamivir therapy appears not to affect the incidence ofneuropsychiatric adverse events in influenza patients. In: Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract V-1223a.